 <b>ExPASy Home page</b>	<b>Site Map</b>	<b>Search ExPASy</b>	<b>Contact us</b>	<b>Swiss-Prot</b>
---	-----------------	----------------------	-------------------	-------------------

Hosted by NCSC US	Mirror sites:	Australia	Bolivia	Canada	China	Korea	Switzerland	Taiwan
-------------------	---------------	-----------	---------	--------	-------	-------	-------------	--------

Search  for

## Search in Swiss-Prot and TrEMBL for: clfa

Swiss-Prot Release 44.2 of 30-Jul-2004

TrEMBL Release 27.2 of 30-Jul-2004

- Number of sequences found in Swiss-Prot<sub>(0)</sub> and TrEMBL<sub>(3)</sub>: 3
- Note that the selected sequences can be saved to a file to be later retrieved; to do so, go to the bottom of this page.
- For more directed searches, you can use the Sequence Retrieval System SRS.

**Search in Swiss-Prot: There are matches to 0 out of 155596 entries**

**Search in TrEMBL: There are matches to 3 out of 1365262 entries**

Q6GIK4

Clumping factor {GENE:Name=clfa; ORFNames=SAR0842} - Staphylococcus aureus subsp. aureus MRSA252

Q8NXJ1

Fibrinogen-binding protein {GENE:Name=clfa} - Staphylococcus aureus (strain MW2)

Q99VJ4


Fibrinogen-binding protein A, clumping factor {GENE:Name=clfa} - Staphylococcus aureus (strain N315)

in Swiss-Prot/TrEMBL by AC, ID, description,  
gene name, organism

**Please do NOT use any boolean operators (and,  
or, etc.)**

If you would like to retrieve all the Swiss-Prot/TrEMBL entries contained in this list, you can enter a file name. These entries will then be saved to a file under this name in the directory outgoing of the ExPASy anonymous ftp server, from where you can download it. (Please note that this temporary file will only be kept for 1 week.)

File name: Format: ☒ Swiss-Prot ☐ Fasta or 

 <a href="#">ExPASy Home page</a>	<a href="#">Site Map</a>	<a href="#">Search ExPASy</a>	<a href="#">Contact us</a>	<a href="#">Swiss-Prot</a>				
<a href="#">Hosted by NCSC US</a>	<a href="#">Mirror sites:</a>	<a href="#">Australia</a>	<a href="#">Bolivia</a>	<a href="#">Canada</a>	<a href="#">China</a>	<a href="#">Korea</a>	<a href="#">Switzerland</a>	<a href="#">Taiwan</a>

0046] As described in the Detailed Description of the Invention hereinbelow, a number of patents and published patent applications describe the gene sequences for fibronectin, fibrinogen, collagen, elastin, and MHC II antigen type binding proteins. These patents and patent applications are incorporated by reference in their entirety. These documents teach that the proteins, fragments, or antibodies immunoreactive with those proteins or fragments can be used in vaccinations for the treatment of S. aureus infections. PCT/US97/087210 discloses the vaccination of mice with a combination of a collagen binding protein (M55 fragment), a fibronectin binding peptide (formalin treated FnBPA (D1-D3)) and a fibrinogen binding peptide (ClfA).

] A mouse mastitis model was used by Mamo, et al., in 1994 (Vaccine, 12:988-992) to study the effect of vaccination with fibrinogen binding proteins (especially FnBP-A) and collagen binding protein from *S. aureus* against challenge infection with *S. aureus*. The mice vaccinated with fibrinogen binding proteins showed reduced rates of mastitis compared with controls. Gross examination of challenged mammary glands of mice showed that the glands of mice immunized with fibrinogen binding proteins developed mild intramammary infection or had no pathological changes compared with glands from control mice. A significantly reduced number of bacteria could be recovered in the glands from mice immunized with fibrinogen binding proteins as compared with controls. Mamo then found that vaccination with FnBP-A combined with staphylococcal alpha toxoid did not improve the protection (Mamo, et al., Vaccine, 12:988-992, 1994). Next, Mamo, et al., immunized mice with only collagen binding protein, which did not induce protection against the challenge infection with *S. aureus*.

CSA 1029 AA  
106, 718 de  
FnBPA AAA-CSA  
989 AA  
1021 407 AA  
Kbp → gene name  
946 aa  
98237 de

first appeared in Japan as  
alleled to the wide use of  
S. aureus or Pseudomonas  
A gyrase was common cause of  
change of drug-permeability  
B, C or nalB are mapped on  
sal membrane proteins dis-  
on to other antibiotics were  
sistant mutants develop with  
is the cause of these resis-

ponents such as fibronectin, various collagens, thrombospondin, vitronectin, laminin and proteoglycan structures such as heparansulphate. Present concepts of how mucosal pathogens associate with receptors in the mucin layer on epithelial cells and in submucosal tissues will be reviewed with examples of host-parasite interactions from different mucosal surfaces with special emphasis on the gastric pathogen Helicobacter pylori and the stomach mucosa. Finally, other pathogens such as staphylococci and Group A, C and G streptococci colonize in open wounds by hydrophobic surface proteins and fibronectin and collagen binding proteins will also be summarized and how this new knowledge of host-parasite receptor ligand interactions may be used to develop anti-adhesion prophylaxis such as adhesin-based vaccines anti-adhesion therapy based on the "hydrophobic principle" will also be summarized with a future perspective in such unconventional strategies to combat infections without using antibiotic and chemotherapeutic compounds.

of antiadhesion strategies  
tions

of Lund, Lund, Sweden

onize teeth and various oral  
otoxigenic Escherichia coli  
er young animals by specific  
ae or pili) have since more  
stigate how microbes inter-  
of the respiratory, gastro-  
that the major viral bac-  
specific surface proteins,  
co-conjugate ligands in the  
als and man. Such receptor  
as well as cell surface  
colipids. Interestingly, a  
us, Mycoplasma pneumoniae,  
nizing animals and man use  
as cell surface adhesins.  
and parasite pathogens can  
colonization by interactions  
nnected tissue matrix com-

## Rapid Detection of Epidemic Strains of Methicillin-Resistant *Staphylococcus aureus*

THOMAS A. WICHELHAUS,\* SYLVIA KERN, VOLKER SCHÄFER,  
AND VOLKER BRADE

Institute of Medical Microbiology, University Hospital of Frankfurt  
am Main, Frankfurt am Main, Germany

Received 1 July 1998/Returned for modification 1 November 1998/Accepted 30 November 1998

Fifty methicillin-resistant *Staphylococcus aureus* (MRSA) initial isolates obtained from patients hospitalized in the orthopedic clinic of the Frankfurt University Hospital and 150 methicillin-sensitive *Staphylococcus aureus* (MSSA) isolates were investigated in this study to determine whether the Slidex Staph-Kit is capable of differentiating between MRSA and MSSA owing to its unique performance characteristics. The Slidex Staph-Kit is a combined latex hemagglutination test designed to detect clumping factor, protein A, and a specific surface immunogen for *S. aureus*. Clumping factor-positive strains agglutinate erythrocytes sensitized with fibrinogen to hemagglutinate, thereby resulting in visible red clumps. *S. aureus* strains deficient in clumping factor agglutinate latex particles sensitized with specific antibodies against surface proteins of *S. aureus*, thereby resulting in visible white clumps. Our results demonstrate that white clumping has a 99% specificity as well as a 98% positive predictive value for MRSA. Clumping factor-negative MRSA, which have been reported to occur in several countries, are epidemic in the Frankfurt area and account for 80% of all MRSA initial isolates in the orthopedic clinic of the Frankfurt University Hospital. Genotyping of all MRSA isolates by macrorestriction analysis of chromosomal DNA revealed that 83% of clumping factor-negative MRSA are closely related to the "southern-German" epidemic strain. This is the first study demonstrating the Slidex Staph-Kit's capability for identifying epidemic clumping factor-negative *S. aureus* strains as methicillin resistant even prior to antimicrobial susceptibility testing.

Methicillin-resistant *Staphylococcus aureus* (MRSA) strains were initially described in 1961 and emerged in the 1980s as a major epidemiological problem in hospital settings (8, 16). MRSA strains with widely different properties have now become endemic in hospitals and are considered important nosocomial pathogens (14, 24, 26). Methicillin resistance rates differ markedly among countries and range from less than 1% in Scandinavia to 60% in Japan (11, 27).

Accordingly, rapid detection of MRSA is crucial for purposes of initiating hygienic measures and preventing further spread of the pathogen. Commercially produced agglutination kits are available for the rapid identification of *S. aureus* by clinical laboratories. Nonetheless, virtually all of them have the drawback that additional time-consuming antimicrobial susceptibility testing generally is required in order to detect methicillin resistance in *S. aureus*.

The aim of this study was to assess the capability and specificity with which the Slidex Staph-Kit differentiates between MRSA and methicillin-susceptible *S. aureus* (MSSA).

### MATERIALS AND METHODS

**Bacterial strains.** A total of 50 MRSA isolates and 150 MSSA isolates were investigated in this study. The MRSA initial isolates were cultured from clinical specimens obtained from the orthopedic clinic of the Frankfurt University Hospital between 1993 and 1997. All isolates had been classified as MRSA during routine investigations and were stored in stock cultures prior to the study, as described previously (29). The MSSA isolates were cultured consecutively from clinical specimens obtained from the Frankfurt University Hospital. *S. aureus* ATCC 25923 was employed as the reference strain.

**Agglutination kits and further characterization.** The Slidex Staph-Kit (bioMérieux Vitex, Inc., Hazelwood, Mo.) is a latex and erythrocyte combination agglutination system for the detection of clumping factor, protein A, and other specific immunogens of *S. aureus*. The Staphylase test (Oxoid, Basingstoke, England) is an erythrocyte agglutination kit for the detection of clumping factor. Both agglutination tests were performed according to the manufacturers' instructions. A tube coagulase test was performed on each isolate. Plasma coagulation was tested with rabbit plasma (Difco, Detroit, Mich.), and the results were read after 2, 4, 6, and 24 h at 37°C. All isolates were screened for hyaluronidase activity by testing the decapsulation reaction on a cross-inoculated streak of a mucous strain of *Streptococcus equi* (9, 19).

**Detection of methicillin resistance.** All of the *S. aureus* isolates were cultured on Mueller-Hinton agar supplemented with 6 µg of oxacillin/ml and 4% NaCl (Biotest, Heidelberg, Germany) (13, 20). The plates were incubated at 30°C for 48 h and examined for evidence of growth to detect resistance phenotypically. The presence of the *mecA* gene was proved for all strains by means of PCR. Purification of bacterial DNA was carried out with the QIAmp tissue kit (Qiagen, Hilden, Germany) in accordance with the manufacturers' instructions. Amplification of the *mecA* gene was performed with the primers *mecA1* (5'-AAA ATC GAT GGT AAA GGT TGG C) and *mecA2* (5'-AGT TCT GCA GTA CCG GAT TTG C), yielding a PCR product of 533 bp (15). DNA amplification was carried out for 30 cycles as previously described (25): denaturation at 94°C for 1 min, annealing at 57°C for 1 min, and extension at 72°C for 2 min, with a final extension at 72°C for 5 min. The PCR product was cleaved by the restriction enzyme *HhaI* (New England Biolabs, Schwalbach, Germany) to confirm the specificity of the *mecA* primers (25). Electrophoresis of DNA was carried out in 2% agarose gel, which was then stained with ethidium bromide and photographed under UV light.

**Genotyping.** All MRSA isolates were analyzed by pulsed-field gel electrophoresis (PFGE) as described previously (29). Briefly, genomic DNA was prepared in low-melting-point agarose plugs and digested with *SmaI* restriction enzyme (New England Biolabs). Electrophoresis was performed on the CHEF-DR III (Bio-Rad Laboratories, Richmond, Calif.) apparatus. A constant voltage of 6 V/cm was applied, with an increasing pulse time of 5 to 50 s over a period of 22 h in order to separate DNA fragments. Computer-aided analysis of DNA fragment patterns was performed with the DNA fingerprint analysis software Wincam 2.2 (Cybertech, Berlin, Germany).

### RESULTS

**Strain characterization.** Coagulase production and hyaluronidase activity was demonstrated for all *S. aureus* isolates in

\* Corresponding author. Mailing address: Institute of Medical Microbiology, University Hospital of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Phone: 49/69/6301-5019. Fax: 49/69/6301-5767. E-mail: Wichelhaus@em.uni-frankfurt.de.




FIG. 1. Agarose gel electrophoresis of *mecA* PCR product. Lanes: M, size markers; 1, *mecA*-positive *S. aureus* strain; 2, restriction of amplified DNA with *HhaI*; 3, *mecA*-negative *S. aureus* reference strain ATCC 25923.

this study. Methicillin resistance was proved genotypically for all isolates by amplification of the *mecA* gene (Fig. 1) as well as phenotypically by growth on Mueller-Hinton agar supplemented with 6 µg of oxacillin/ml and 4% NaCl.

**Genotyping.** Macrorestriction analysis of 50 MRSA initial isolates obtained from the orthopedic clinic of the Frankfurt University Hospital in a 5-year period revealed 18 different genotypes (Fig. 2). Fifty percent of all isolates belonged to type 1, and strongly corresponding restriction fragment patterns indicating close clonal relatedness between MRSA types 1, 7, 71, and 72 were obvious (Fig. 3).

**Agglutination performance.** Table 1 compares the performance of the Slidex Staph-Kit with that of the Staphylase agglutination test. It could be demonstrated that all MRSA initial isolates closely related to the epidemic strain, as well as isolates belonging to MRSA types 6, 76, 82, and 83 exhibited white-clumping behavior (Fig. 4). In every instance where the Slidex Staph-Kit exhibited white clumping the Staphylase agglutination test was negative, which indicates that these strains were at least phenotypically clumping factor negative. In contrast, 149 of 150 MSSA isolates classified during routine investigation were determined to be clumping factor positive, i.e., they exhibited red-clumping behavior (Fig. 5).

## DISCUSSION

Rapid and accurate identification of methicillin resistance in *S. aureus* is of ongoing clinical importance for controlling the spread of this pathogen within hospital settings. The plasma coagulase test is generally acknowledged as the "gold standard" for the identification of *S. aureus*. Nevertheless, the use of commercial agglutination kits for identifying *S. aureus* is widespread in clinical microbiological laboratories, since these tests are easy to perform and the results are available within minutes. Whereas the first-generation agglutination kits are capable of detecting clumping factor and/or protein A for *S. aureus* strains while failing to identify certain MRSA strains (3, 22), second-generation agglutination kits, such as the Slidex Staph-Kit, possess the additional feature of being able to detect specific surface antigens for *S. aureus*. Numerous studies have been published confirming the high sensitivity and spec-




FIG. 2. PFGE patterns of *SmaI* digests of total DNA from representatives of each pulsotype (indicated by numbers above lanes). Lanes M, size markers. Molecular sizes (in kilobases) are indicated on the right.

ificity of these second-generation kits for the identification of MSSA as well as MRSA (1, 4-6, 10, 17, 23, 30). Definitive detection of methicillin resistance, however, still requires time-consuming antimicrobial susceptibility testing.




FIG. 3. Computer-aided analysis of different PFGE types, indicating clonal relatedness.

TABLE 1. Performance of the Slidex Staph-Kit and Staphylase test for the identification of MRSA and MSSA

Organism	Type	n	Results <sup>a</sup>	
			Slidex Staph-Kit	Staphylase test
MRSA	1	25	W	-
	7	2	W	-
	71	3	W	-
	42	1	W	-
	72	1	W	-
	73	1	W	-
	74	1	W	-
	75	1	R	R
	6	1	W	-
	76	1	W	-
	77	1	R	R
	78	2	R	R
	79	1	R	R
	80	2	R	R
	81	2	R	R
	41	1	R	R
	83	2	W	-
	82	2	W	-
MSSA		150	R/W <sup>b</sup>	ND

<sup>a</sup> W, white clumping; R, red clumping; -, no clumping; ND, not determined.

<sup>b</sup> RAW, both R (n = 149) and W (n = 1).

This is the first study demonstrating that the Slidex Staph-Kit is a reliable and, above all, rapid method for identifying epidemic clumping factor-negative MRSA even prior to antimicrobial susceptibility testing. Owing to its unique design as a combined latex and hemagglutination test, it reacts, in contrast to all the other latex agglutination kits, in two different ways. Red clumps indicate the presence of clumping factor, with which *S. aureus* causes erythrocytes sensitized with fibrinogen to agglutinate (Fig. 5). White clumps, on the other hand, signal both the absence of clumping factor and the presence of other immunogens, which trigger the agglutination of the latex particles (Fig. 4). This study shows that white clumping has a 99% specificity and a 98% positive predictive value for the detection of methicillin resistance in *S. aureus*. Fifty percent of all initial isolates obtained from the orthopedic clinic of the Frankfurt University Hospital and more than 60% of all initial isolates in




FIG. 4. Performance characteristics of Slidex Staph-Kit: white clumping. Magnification, ca.  $\times 2$ .

COPY CLIN. MICROBIOL.




FIG. 5. Performance characteristics of Slidex Staph-Kit: red clumping. Magnification, ca.  $\times 2.5$ .

the Frankfurt metropolitan area, including six community hospitals and the University Hospital (29), belong to one genotype, which has been identified by the Robert Koch Institute, the German national institute of infectious diseases, as the so-called "southern-German" epidemic strain. This epidemic strain is clumping factor negative and exhibits white-clumping behavior. Furthermore, it is not only epidemic in the south but is also widespread in the northern parts of Germany (22, 31). Since bacteria do not respect international boundaries, it came as no surprise when epidemic MRSA strains kindly sent to our institution from Slovakia and Italy exhibited the same southern-German genotype and showed white-clumping behavior (data not shown). As demonstrated by PFGE in this study, it is not only the southern-German epidemic strain which is clumping factor negative; other MRSA genotypes also manifest this typical agglutination characteristic.

The Slidex Staph-Kit, of course, is neither designed nor licensed to detect resistance, and as such, white clumping can be regarded only as a clue to methicillin resistance. Nonetheless, to the extent that the white clumping serves as a strong indicator for MRSA, rapid tests can be conducted which confirm methicillin resistance and, upon request, species identity within 4 hours. This validation can be achieved genotypically, for example, by multiplex PCR, a method that enables the detection of the *mecA* gene and a species-specific gene for *S. aureus* within 5 to 6 h (2, 21). Quicker and less labor intensive is the phenotypical verification of MRSA with the BBL Crystal MRSA ID system from Becton Dickinson, which can be performed within 4 h (12, 18, 28). Finally, the phenotypical test for plasma coagulation can be performed to confirm spe-




FIG. 6. Procedure for the rapid identification of clumping factor-negative MRSA with the Slidex Staph-Kit.



cies specificity, analogous to the genotypic confirmation by multiplex PCR (7) (Fig. 6).

The results of this study, as well as the fact that a modern second-generation agglutination test was required owing to the rising incidence of clumping factor-negative MRSA, indicate that all clumping factor-negative MRSA strains are capable of being recognized by the Slidex Staph-Kit with its differentiated agglutination characteristics. In view of these findings, the Slidex Staph-Kit is a valuable tool in clinical laboratories with a frequent occurrence of clumping factor-negative MRSA.

In conclusion, this study confirms the Slidex Staph-Kit's ability within the context of the clinical microbiological laboratory to pinpoint certain epidemic MRSA strains 24 h prior to the final results provided by antimicrobial susceptibility testing. In turn, the initiation of effective infection control measures may reduce the spread of this pathogen.

#### REFERENCES

- Adams, J., and R. Van Enk. 1994. Use of commercial particle agglutination systems for the rapid identification of methicillin-susceptible and methicillin-resistant *Staphylococcus aureus*. *Eur. J. Clin. Microbiol. Infect. Dis.* 13:86-89.
- Brakstad, O. G., Y. Tveten, F. Nato, and J. M. Fournier. 1993. Comparison of various methods and reagents for species identification of *Staphylococcus aureus* positive or negative for the *mecA* gene. *APMIS* 101:651-654.
- Croize, J. P., P. Gialanella, D. Monnet, J. Okada, A. Orsi, A. Voss, and S. Merlin. 1993. Improved identification of *Staphylococcus aureus* using a new agglutination test. Results of an international study. *APMIS* 101:487-491.
- Davies, S. 1997. Detection of methicillin-resistant *Staphylococcus aureus*: the evaluation of rapid agglutination methods. *Br. J. Biomed. Sci.* 54:13-15.
- Felten, A., E. Lepage, and P. Lagrange. 1995. Critical analysis of tests for rapid detection of *Staphylococcus aureus*, *Pastorex Staph plus*, *Slidex Staph-Kit* and *Staph aureus* in clinical isolates. *Pathol. Biol.* 43:471-476.
- Fournier, J. M., A. Bouvet, D. Mathieu, F. Nato, A. Boutonnier, R. Gerbal, P. Brunengo, C. Saulnier, N. Sagot, B. Slizewicz, and J. C. Mazie. 1993. New latex reagent using monoclonal antibodies to capsular polysaccharide for reliable identification of both oxacillin-susceptible and oxacillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 31:1342-1344.
- Janda, W. M., K. Ristow, and D. Novak. 1994. Evaluation of RapiDEC Staph for identification of *Staphylococcus aureus*, *Staphylococcus epidermidis*, and *Staphylococcus saprophyticus*. *J. Clin. Microbiol.* 32:2056-2059.
- Jevons, M. P. 1961. "Celbenin"-resistant staphylococci. *Br. Med. J.* 1:124-125.
- Kafka, A. 1957. Erfahrungen mit einfachen Untersuchungsmethoden zum Nachweis von Hyaluronidase, Fibrinolysin und Phosphatase bei Staphylokokken. *Zentbl. Bakteriol.* 168:381-385.
- Kampf, G., K. Weist, S. Swidsinski, M. Kegel, and H. Rüden. 1997. Comparison of screening methods to identify methicillin-resistant *Staphylococcus aureus*. *Eur. J. Clin. Microbiol. Infect. Dis.* 16:301-307.
- Kimura, A., H. Igarashi, H. Ushioda, K. Okuzaki, H. Kobayashi, and T. Otsuka. 1992. Epidemiological study of *Staphylococcus aureus* isolated from Japanese national university and medical college hospitals. *Kansenshogaku Zasshi* 66:1543-1549.
- Knapp, C. C., M. D. Ludwig, and J. A. Washington. 1994. Evaluation of BBL Crystal MRSA ID system. *J. Clin. Microbiol.* 32:2588-2589.
- Mackenzie, A. M. R., H. Richardson, R. Lannigan, and D. Wood. 1995. Evidence that the National Committee for Clinical Laboratory Standards disk test is less sensitive than the screen plate for detection of low-expression-class methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 33:1909-1911.
- Michel, M., and L. Gutmann. 1997. Methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant enterococci: therapeutic realities and possibilities. *Lancet* 349:1901-1906.
- Murakami, K., W. Minamide, K. Wada, E. Nakamura, H. Terakura, and S. Watanabe. 1991. Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. *J. Clin. Microbiol.* 29:2240-2244.
- Pantilio, A. L., D. H. Culver, R. P. Gaynes, S. Banerjee, T. S. Henderson, J. S. Tolson, and W. J. Martone. 1992. Methicillin-resistant *Staphylococcus aureus* in U.S. hospitals, 1975-1991. *Infect. Control Hosp. Epidemiol.* 13:582-586.
- Personne, P., M. Bex, G. Lina, F. Vandenesch, Y. Bram, and J. Etienne. 1997. Comparative performances of six agglutination kits assessed by using typical and atypical strains of *Staphylococcus aureus*. *J. Clin. Microbiol.* 35:1138-1140.
- Qadri, S. M. H., Y. Ueno, H. Inanbaccus, and E. Almodovar. 1994. Rapid detection of methicillin-resistant *Staphylococcus aureus* by Crystal MRSA ID system. *J. Clin. Microbiol.* 32:1830-1832.
- Raus, J., and D. N. Joyce. 1983. Characterization of coagulase positive *Staphylococcus intermedius* and *Staphylococcus aureus* isolated from veterinary clinical specimens. *J. Clin. Microbiol.* 18:789-792.
- Schmalreck, A. F., W. Friedrich, I. Kottmann, A. Reiser, U. Rüfer, R. Schlenk, P. Tränkle, E. Vanca, and A. Wildfeuer. 1996. Resistenzmuster von Staphylokokken und Nachweis des *mecA*-Gens. *Chemother. J.* 4:195-202.
- Schmitz, F. J., B. Hofmann, M. Finken-Eigen, H. Idel, U. Hadding, H. P. Heinz, and K. Köhrer. 1996. Etablierung einer Multiplex-PCR mit Aussagen zur Taxonomie, Pathogenität und Methicillin-Resistenz bei Staphylokokken. *J. Lab. Med.* 20:543-550.
- Schwarzkopf, A., H. Karch, H. Schmidt, W. Lenz, and J. Heesemann. 1993. Phenotypical and genotypical characterization of epidemic clumping factor-negative, oxacillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.* 31:2281-2285.
- Smole, S. C., E. Aronson, A. Durbin, S. M. Brecher, and R. D. Arbeit. 1998. Sensitivity and specificity of an improved rapid latex agglutination test for identification of methicillin-sensitive and -resistant *Staphylococcus aureus* isolates. *J. Clin. Microbiol.* 36:1109-1112.
- Speller, D. C. E., A. P. Johnson, D. James, R. R. Marples, A. Charlett, and R. C. George. 1997. Resistance to methicillin and other antibiotics in isolates of *Staphylococcus aureus* from blood and cerebrospinal fluid, England and Wales, 1989-95. *Lancet* 350:323-325.
- Ungeheuer, J., S. Wilms, and W. Sietzen. 1994. *mecA*-Gen bei Staphylokokken—vereinfachter Nachweis mit der PCR. *Chemother. J.* 1:31-35.
- Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M. H. Nicolas-Chanoine, M. Wolff, R. C. Spencer, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care units in Europe. *JAMA* 274:639-644.
- Voss, A., D. Milatovic, C. Wallrauch-Schwarz, V. T. Rosdahl, and I. Braveny. 1994. Methicillin-resistant *Staphylococcus aureus* in Europe. *Eur. J. Clin. Microbiol. Infect. Dis.* 13:50-55.
- Wallet, F., M. Roussel-Delvallez, and R. J. Courcol. 1996. Choice of a routine method for detecting methicillin-resistance in staphylococci. *J. Antimicrob. Chemother.* 37:901-909.
- Wichelhaus, T. A., J. Schulte, K. P. Hunfeld, V. Schäfer, and V. Brude. 1997. Clonal heterogeneity, distribution, and pathogenicity of methicillin-resistant *Staphylococcus aureus*. *Eur. J. Clin. Microbiol. Infect. Dis.* 16:893-897.
- Wilkerson, M., S. McAllister, J. M. Miller, B. J. Heiter, and P. P. Bourbeau. 1997. Comparison of five agglutination tests for identification of *Staphylococcus aureus*. *J. Clin. Microbiol.* 35:148-151.
- Witte, W., C. Cuny, C. Bräulke, and D. Hueck. 1994. Clonal dissemination of two MRSA strains in Germany. *Epidemiol. Infect.* 113:67-73.